MA38131A3 - Kinase inhibitor adjuvant therapy of the tec family - Google Patents

Kinase inhibitor adjuvant therapy of the tec family

Info

Publication number
MA38131A3
MA38131A3 MA38131A MA38131A MA38131A3 MA 38131 A3 MA38131 A3 MA 38131A3 MA 38131 A MA38131 A MA 38131A MA 38131 A MA38131 A MA 38131A MA 38131 A3 MA38131 A3 MA 38131A3
Authority
MA
Morocco
Prior art keywords
kinase inhibitor
tec family
adjuvant therapy
inhibitor adjuvant
therapy
Prior art date
Application number
MA38131A
Other languages
French (fr)
Other versions
MA38131A2 (en
Inventor
Joseph Buggy
Tarak Mody
Richard Love
John Byrd
Betty Chang
Jason Dubovsky
Natarajan Muthusamy
Amy Johnson
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/068132 external-priority patent/WO2014071231A1/en
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of MA38131A2 publication Critical patent/MA38131A2/en
Publication of MA38131A3 publication Critical patent/MA38131A3/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés et des compositions comprenant un inhibiteur de kinase covalent de la famille tec destiné à être utilisé dans une thérapie adjuvante, notamment une thérapie adjuvante anticancéreuse, une vaccination et un traitement de troubles immunitaires et d'infections pathogènes.The present invention provides methods and compositions comprising a covalent kinase inhibitor of the tec family for use in adjuvant therapy, including adjuvant anticancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

MA38131A 2012-11-02 2015-05-26 Kinase inhibitor adjuvant therapy of the tec family MA38131A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722107P 2012-11-02 2012-11-02
PCT/US2013/068132 WO2014071231A1 (en) 2012-11-02 2013-11-01 Tec family kinase inhibitor adjuvant therapy

Publications (2)

Publication Number Publication Date
MA38131A2 MA38131A2 (en) 2016-11-30
MA38131A3 true MA38131A3 (en) 2018-05-31

Family

ID=58501204

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38131A MA38131A3 (en) 2012-11-02 2015-05-26 Kinase inhibitor adjuvant therapy of the tec family

Country Status (1)

Country Link
MA (1) MA38131A3 (en)

Also Published As

Publication number Publication date
MA38131A2 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
EA201590822A1 (en) ADJUVANT THERAPY INHIBITOR KINASE OF THE FAMILY TEC
MA41013B1 (en) Compositions comprising bacterial strains
BR112015011456A2 (en) aminopyrimidine compounds as t790m-containing mutant egfr inhibitors
MA39094A1 (en) Combination therapy comprising an inhibitor of mdm2 and one or more additional pharmaceutically active principles for the treatment of cancers
MX355065B (en) Laquinimod for reducing thalamic damage in multiple sclerosis.
PE20151070A1 (en) TYROSINE INHIBITORS - BRUTON KINASE
MX360045B (en) Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor.
BR112013008140A2 (en) "imidazotriazinone compounds".
EA201590655A1 (en) COMBINATION OF LACHINIMODE AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
MA39725B1 (en) Pharmaceutical compositions of therapeutically active compounds
MX2019004859A (en) Combination treatments comprising administration of imidazopyrazinones.
BR112016028446A2 (en) ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism
MA35281B1 (en) Assay and administration of anti-erbb3 antibodies in combination with paclitaxel for the treatment of gynecological cancers
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
MA39447A1 (en) (s) -pirlindole or its pharmaceutically acceptable salts for use in medicine
MA43294A1 (en) 1-methyl-d-tryptophan salts and prodrugs
MA39448B1 (en) (r) -pirlindole and its pharmaceutically acceptable salts for medical use
MA39228A1 (en) Compositions for use in treating allergic conditions
MA38131A2 (en) Kinase inhibitor adjuvant therapy of the tec family
FR3061021B1 (en) ANTAGONIST SPECIFIC TO TLR4 IN THE TREATMENT OF MULTIPLE MYELOMA
CY1118255T1 (en) Substituted 6-amino-nicotinamides which carry a group containing KCNQ2 / 3 modulators
FR3074421B1 (en) HELICHRYSUM GYMNOCEPHALUM EXTRACT FOR THE TREATMENT AND / OR PREVENTION OF INFLAMMATORY DERMATOSIS
MA51185A (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201491291A1 (en) AGONISTS mGlu 2/3
MA37957A1 (en) Methods of treating alzheimer's disease and associated pharmaceutical compositions